Previous 10 | Next 10 |
The FDA has approved Aerie Pharmaceuticals' (NASDAQ: AERI ) sterile fill production facility in Athlone, Ireland for production of Rhopressa (netarsudil ophthalmic solution) 0.02% for commercial distribution in the U.S. More news on: Aerie Pharmaceuticals, Inc., Healthcare st...
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that i...
Aerie Pharmaceuticals ( AERI +2.9% ) was initiated by Guggenheim analyst Dana Flanders with a Buy rating and price target of $20, indicating a upside of 67.8% from current levels. More news on: Aerie Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read mor...
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that t...
Graybug Vision (GRAY) has filed a preliminary prospectus for an $86M IPO. More news on: Roche Holding AG, REGENXBIO Inc., Opthea Limited, Healthcare stocks news, IPO News, , Read more ...
Aerie Pharmaceuticals, Inc. (AERI) Q2 2020 Earnings Conference Call August 6, 2020 17:00 ET Company Participants Ami Bavishi - Director of Investor Relations Vicente Anido - Chairman & Chief Executive Officer Tom Mitro - President & Chief Operating Officer Rich Rubino -...
Image source: The Motley Fool. Aerie Pharmaceuticals Inc (NASDAQ: AERI) Q2 2020 Earnings Call Aug 7, 2020 , 11:00 a.m. ET Operator Continue reading
Aerie Pharmaceuticals (NASDAQ: AERI ) : Q2 Non-GAAP EPS of -$0.83 misses by $0.03 ; GAAP EPS of -$1.05 misses by $0.04 . More news on: Aerie Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Year-to-Date Net Revenues of $38.4 Million Increased 44% over 2019 Positive Phase 2 Topline Results for AR-1105 Implant Indicate up to Six-Month Sustained Release AR-15512 Trial for Dry Eye, COMET-1, Set to Initiate this Year Conference Call and Webcast Today, August 6 th , a...
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that it...
News, Short Squeeze, Breakout and More Instantly...
Aerie Pharmaceuticals Inc. Company Name:
AERI Stock Symbol:
NASDAQ Market:
Aerie Pharmaceuticals Inc. Website:
Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Al...
Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceut...
NEW YORK, NY / ACCESSWIRE / October 30, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Altra Industrial Motion Corp. (NA...